Watson Licenses North American Rights to Silodosin from Kissei
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 48 (Table of Contents)
Published: 4 Jun-2004
DOI: 10.3833/pdr.v2004.i48.803 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Kissei granted Watson, the exclusive rights to develop and commercialise KMD-3213 (silodosin) in North America...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS